Physician profile
Joseph Buglisi
NPI 1083821789
$1,727.13
in general payments reported to CMS, 2019-2025
15 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $279 · 2021: $287 · 2022: $153 · 2023: $136 · 2024: $492 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $441.36 | 2021-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $310.81 | 2019-2021 | |
| Allergan, INC. | $197.32 | 2020-2022 | |
| Alcon Vision LLC | $171.17 | 2022-2025 | Clareon, Tryptyr, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $157.39 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Surgical Misc |
| Sight Sciences, INC. | $129.79 | 2020-2024 | Omni Surgical System |
| Abbvie INC. | $74.91 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $60.15 | 2025 | |
| Glaukos Corporation | $41.94 | 2022-2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Kala Pharmaceuticals, INC. | $33.25 | 2019-2021 | |
| Dompe US, INC. | $28.95 | 2022 | |
| Eyepoint US, INC. | $28.12 | 2021 | |
| Staar Surgical Company | $20.00 | 2019 | |
| Ocular Therapeutix, INC. | $18.27 | 2021 | |
| Omeros Corporation | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Buglisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.